• Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214 americanpharmaceuticalreview
    September 14, 2020
    Viking Therapeutics announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available thyroid receptor beta (TRβ) agonist in development as a potential treatment for ...
  • Viking Therapeutics Announces Positive Top-Line Results of VK2809 Study americanpharmaceuticalreview
    September 20, 2018
    Viking Therapeutics announced positive top-line results from a 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein choles
PharmaSources Customer Service